Adverse effects (number of participants who had the event) · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with meglumine antimoniate (20 mg/kg 20 days) (moderate certainty).
1 finding from 1 review
Recurrence ‐ not measured · People with American cutaneous and mucocutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement of quality of life · people with mycosis fungoides
The review found no eligible studies for this question.
1 finding from 1 review
Common adverse effects ‐ Photosensitivity (Time point of measurement: up to 16 weeks) · people with mycosis fungoides
Bexarotene + PUVA showed no clear difference in common adverse effects ‐ Photosensitivity (Time point of… compared with PUVA alone (low certainty).
1 finding from 1 review
Complete response · people with mycosis fungoides
Bexarotene + PUVA showed no clear difference in complete response (Time point of measurement: up to 16 weeks) compared with PUVA alone (low certainty).
1 finding from 1 review
Objective response rate · people with mycosis fungoides
Bexarotene + PUVA showed no clear difference in objective response rate (Time point of measurement: up to 16 weeks) compared with PUVA alone (low certainty).
1 finding from 1 review
Improvement of quality of life · people with mycosis fungoides
The review found no eligible studies for this question.
1 finding from 1 review
Adverse event (flu‐like symptoms) · people with mycosis fungoides
IFN‐α + acitretin showed no clear difference in common adverse effects ‐ Flu‐like symptoms (Time point of… compared with IFN‐α + PUVA (low certainty).
1 finding from 1 review
Complete response · people with mycosis fungoides
IFN‐α + acitretin may leads to lower complete response (Time point of measurement: up to 48 weeks or… compared with IFN‐α + PUVA (low certainty).
1 finding from 1 review
Objective response rate · people with mycosis fungoides
The review found no eligible studies for this question.
1 finding from 1 review
Improvement of quality of life · people with mycosis fungoides
1 finding from 1 review
Common adverse effects · people with mycosis fungoides
1 finding from 1 review
Complete response · people with mycosis fungoides
1 finding from 1 review
Common adverse effects · people with mycosis fungoides
The review found no eligible studies for this question.
1 finding from 1 review
Objective response rate · people with mycosis fungoides
1 finding from 1 review
Complete response · people with mycosis fungoides
IFN‐α + PUVA showed no clear difference in complete response (CR) compared with PUVA alone (low certainty).
1 finding from 1 review
Objective response rate · people with mycosis fungoides
The review found no eligible studies for this question.
1 finding from 1 review
Improvement of quality of life · people with mycosis fungoides
The review found no eligible studies for this question.
1 finding from 1 review
Common adverse effects · people with mycosis fungoides
1 finding from 1 review
Complete response · people with mycosis fungoides
It is very uncertain whether extracorporeal photopheresis changes complete response (Time point of measurement: three months of PUVA… compared with PUVA (very low certainty).
1 finding from 1 review